Results 111 to 120 of about 3,132 (216)

Improving Clinic Capacity with Faricimab

EMJ Innovations
Clinic capacity constraints are an ever-increasing problem in ophthalmology. Multiple case studies demonstrate that faricimab frees up clinic capacity with extended treatment intervals in both treatment-naïve and treatment-experienced patients. In this symposium, three case studies from the UK and Spain demonstrated how fewer appointments per patient ...
David Wong, Romi Chhabra, Jorge Ruiz-Medrano, Robin Hamilton   +3 more
openaire   +1 more source

Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema

Eye
Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial
Grace A. Borchert, Christine A. Kiire, Niamh Stone, H. Akil, Theodora Gkika, M. Fischer, Kanmin Xue, Jasmina Cehajic-Kapetanovic, Robert E. MacLaren, Peter Charbel Issa, S. M. Downes, S. D. De Silva   +11 more
semanticscholar   +1 more source

Efficacy and Safety of Faricimab in Diabetic Macular Edema: Real-World Outcomes in Treatment-Naïve and Previously Treated Eyes

Journal of Clinical Medicine
Background: The objective of this study was to assess the efficacy and safety of faricimab in diabetic macular edema (DME) in patients who were treatment-naïve or previously treated in a real-world setting.
Olivia Esteban-Floría, Javier Mateo, J. Lara, Isabel Bartolomé, Inmaculada Herrero, M. Pérez, C. Cabello, A. Honrubia, I. Pinilla, J. Ascaso   +9 more
semanticscholar   +1 more source

INTRAVITREAL FARICIMAB AS AN ADJUVANT IN THE MANAGEMENT OF TUBERCULAR UVEITIS

RETINAL Cases & Brief Reports
Purpose: The objective of this study was to report the use of intravitreal faricimab used as an adjunct in the management of intraocular tuberculosis in a patient with occlusive retinal vasculitis and choroiditis.
Yasmine Alcibahy, Karina Julian, Maria Fernanda Bonilla, Ali Mohamed, Sarah Amrani, Aniruddha Agarwal   +5 more
openaire   +2 more sources

Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration

Scientific Reports
We evaluated the efficacy of switching to intravitreal injection of faricimab (IVF) in patients with aflibercept-refractory neovascular age-related macular degeneration (nAMD) over 2 years of follow-up.
Masaaki Saito, Kimihiro Imaizumi
semanticscholar   +1 more source

Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema

PURPOSE: To assess the effectiveness of a switch to faricimab in individuals affected by DME and previously treated with aflibercept. METHODS: In this retrospective, single-center study, DME patients previously treated with at least 3 injections of ...
Aljneibi, Shaikha, Ghazi, Nicola G, El Ghrably, Ibraheem, Pichi, Francesco, Agarwal, Aniruddha, Abdi, Abdulhamid   +5 more
core   +1 more source

Faricimab in the Treatment of Exudative Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Italy: The FARIT Real World Study

Ophthalmology and Therapy
Faricimab is a bispecific antibody that enables greater disease control and extended durability compared with vascular endothelial growth factor (VEGF) inhibition alone in neovascular age-related macular degeneration (nAMD) and diabetic macular edema ...
M. Lupidi, C. Iaculli, Luisa Marco, Settimio Rossi, E. Sicari, Giulia Villa, Vittorio Pirani   +6 more
semanticscholar   +1 more source

Sorprendente regresión completa de una membrana neovascular coroidea con faricimab

Retinografía de DMAEnv antes y después del tratamiento. En la OCT estructural y la OCTA se aprecia MNC tipo1 activa. Se inicia tratamiento con anti-VEGF (proteína de fusión contra VEGF-A, VEGF-B y PIGF) en pauta T&E con control de la exudación ...
Duch Samper, Antonio Miguel, Ruiz del Rio, Noemí, García Ibor, Francisca   +2 more
core   +1 more source

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmology
Faricimab is a novel anti-vascular endothelial growth factor agent, used to treat patients with neovascular age-related macular degeneration (nAMD). This study assessed efficacy and safety of faricimab in previously treated eyes. This retrospective study
M. Bantounou, M. Elsheikh, Adelehin Ijasan, C. Santiago   +3 more
semanticscholar   +1 more source

Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature

Eye and Vision
Background This article describes a rare occurrence of bilateral retinal occlusive vasculitis secondary to intravitreal faricimab injection. Case presentation A 72-year-old female with age-related macular degeneration presented with bilateral retinal ...
Yong Min Lee, Rajya Gurung, Jagjit Singh Gilhotra, Sumu Simon, Sudha Cugati   +4 more
doaj   +1 more source